Reality Check on COPD
Market access for COPD treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, more than half of the lives under all three formularies are covered without utilization management restrictions
- Class Trends: Highmark Inc. said in April 2018 that it is working with AstraZeneca under an agreement for Symbicort, a medication used to improve lung function in patients with asthma and chronic obstructive pulmonary disease
- Key Findings: In January 2019, the FDA approved the first generic of GSK's Advair Diskus, which is manufactured by Mylan
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.